The OPG/RANKL/RANK system and bone resorptive disease.
- Author:
Ji-Zhong LIU
1
;
Zong-Ling JI
;
Su-Min CHEN
Author Information
1. The Forth Military Medical University, Institute of Orthopaedics, Xi' an 710032, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Bone Resorption;
immunology;
metabolism;
Humans;
Osteoclasts;
cytology;
metabolism;
pathology;
Osteogenesis;
drug effects;
genetics;
immunology;
Osteoprotegerin;
metabolism;
physiology;
RANK Ligand;
metabolism;
physiology;
Receptor Activator of Nuclear Factor-kappa B;
metabolism;
pharmacology;
physiology;
T-Lymphocytes;
drug effects;
immunology
- From:
Chinese Journal of Biotechnology
2003;19(6):655-660
- CountryChina
- Language:Chinese
-
Abstract:
The OPG/RANKL/RANK system plays an important role in osteoclastogenesis and represents a great progress in bone biology. RANKL, which expresses on the surface of osteoblast/stromal cells and activated T cells, binds to RANK on the osteoclastic precursors or mature osteoclasts, and promotes osteoclastogenesis and bone resorption. While osteoprotegerin (OPG), which is expressed by osteoblasts/stromal cells, strongly inhibits bone resorption by binding to its ligand RANKL and thereby blocks the interaction between BANKL and RANK. A number of cytokines and hormones exert their effects on bone metabolism by regulating the OPG/RANKL ratio in the bone marrow microenvironment. RANK is also expressed on mammary epithelial cells and RANKL expression in these cells is induced by pregnancy hormones, RANKL and RANK are essential for the formation of the lactating mammary gland and the transmission of maternal calcium to neonates in mammalian species. Modulation of these systems provides a unique opportunity to develop novel therapeutics to inhibit bone loss in osteoporosis, rheumatoid arthritis, and bone metastasis of cancer. Further research should be focused on the cooperation of OPG/RANKL/RANK system with other signal pathways and the interactions among bone remodeling, immune system and endocrinology system. Currently, the development of OPG analogues or compounds which may stimulate OPG expression is becoming an attractive industry which may be profitable to both patients and manufacturers.
